Drug Design Development and Therapy · 2020 · 20 citations · 14 references
Life SciencesMolecular BiologyToxicologyGene ExpressionInflammationTranscriptomicsLipid MetabolismLipid-lowering TherapyLipidomicsLipoprotein MetabolismMolecular Mechanisms Of ToxicityReactive Oxygen SpeciesAtherosclerosis Molecular MechanismsAtherosclerosis-associated MacrophagesAtherosclerotic Lipid AccumulationAtherosclerotic ProgressionFoam FormationLow-density Lipoprotein ParticlesLow-density Lipoprotein UptakeMicroarray Analysis
PURPOSE: Isoborneol has been used in the treatment of cardiovascular disease for several years in China. However, the mechanism is still unclear. The aim of this study was to identify the novel mechanism of isoborneol for its application in atherosclerotic disease. MATERIALS AND METHODS: The whole-genome gene expression profiles of MCF-7 cells treated with/or without isoborneol were detected by mRNA microarray analysis. The degree of similarity between the gene expression profiles was compared with the Connectivity Map (CMAP) database. An MTT assay was used to assess the toxicity of isoborneol on RAW 264.7 cells. Oil red O staining and a Dil-ox-LDL uptake assay in RAW 264.7 cells were also used to detect the accumulation of lipids in the macrophages and the uptake of oxidized low-density lipoprotein (ox-LDL). RESULTS: Isoborneol was proved to have mRNA expression profiles similar to that of ikarugamycin which can inhibit the uptake of ox-LDL. This process has proved to be an important cause of foam cell formation and early atherosclerotic lesions. It is speculated, therefore, that isoborneol may show similar activity to that shown by ikarugamycin. Subsequently, it was shown that RAW 264.7 cells reduced the absorption of ox-LDL and the accumulation of intracellular lipids after treatment with different concentrations of isoborneol. CONCLUSION: The results indicate that isoborneol inhibits macrophage consumption of ox-LDL, thereby preventing the accumulation of lipids in the macrophages. These results provide evidence for the application of isoborneol in atherosclerotic disease.
14
Damian Szklarczyk, Annika L. Gable, David Lyon et al. · Nucleic Acids Research · 2018 · 19.2K citations · Full text
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Emelia J. Benjamin, Paul Muntner, Álvaro Alonso et al. · Circulation · 2019 · 9.1K citations · Full text
Inflammation in Atherosclerosis
Juno Deguchi, Masanori Aikawa, Ching‐Hsuan Tung et al. · Circulation · 2006 · 419 citations
Medicine, Pathobiology, Pathology +17